How A Tool For Scientists Became A Billion-Dollar Opportunity | Forbes

Sajith Wickramasekara was an undergrad at MIT when he came up with the idea for a cloud-based Crispr design tool to help scientists. Eight years later, Regeneron, Gilead and hundreds of other companies use its collaborative R&D software, and the company boasts a roaster of investors that includes Andreessen Horowitz, Benchmark, Menlo Ventures, Thrive Capital, and Y Combinator. As many customers rush to come up with vaccines and treatments for Covid-19, Benchling is on call as needed—but has stopped pushing software updates to those whose projects require total lockdown.

Stay Connected

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

[kakashie]

3 mins, no description of what the company actually does ...

[kuntakinte]

Super informative video! Just one typo: In the description his first name is incorrectly typed as 'Eric', but I think it was meant to be 'Sajith' Wickramasekara. :-)

*Edit: Thanks for correcting it!* 👍🏿

[ProfessionalTycoons]

smart guy started as a hobby now a enterprise

[juvent.h]

That is great, so basically the Coronavirus has struck this startup with a huge opportunity like for Zoom?

[b-sahil]

do you think i should run after finding an idea or will it strike me when the time is right??? please let me know . i have been struggling from few months

[AA-uuik]

But how does it actually work??? This video doesn’t show HOW this improves collaboration etc between scientists. Journalist was clearly not from a scientific background

[katherinealejandraleivavel]

Is it like Nunu? Or did I understood wrong?

[raunakthakur]

Bunching group of data from around the world helping scientists understand covid19 effect

[MrTimetravler]

an no clue on what the hell is benchling?